Advances in Mass Spectrometry‐Based Proteomics for Kidney Disease Biomarker Discovery and Clinical Translation
Mass Spectrometry Reviews · 2026-08-22
DOI: 10.1002/mas.70041 ↗At a glance
Übersichtsarbeit in Mass Spectrometry Reviews, published online on 2026-08-22. Written by Yingying Ling and 10 co-authors. Institution: Department of Nephrology, Frontiers Science Center for Disease-related Molecular Network, Institutes for Systems Genetics, West China Hospital, Sichu…. 305 references. Funded by: National Natural Science Foundation of China, National Key R&D Program of China.
Abstract (original language)
The high prevalence and substantial burden of kidney diseases necessitate advanced approaches to elucidate molecular mechanisms and promote precision medicine. Mass spectrometry (MS)‐based proteomics has evolved into a widely used analytical platform, delivering high‐sensitivity, high‐throughput protein profiling capabilities that have contributed substantially to biomarker discovery, mechanistic dissection, and therapeutic target identification across a broad range of kidney diseases. This review provides a comprehensive overview of MS‐based proteomics applications in kidney disease research, covering progress in biomarker identification, pathogenic mechanism interrogation, and clinical translation. It highlights methodological advances, emerging trends, and persistent challenges that shape the field. Existing literature has uncovered abundant disease‐specific biomarkers and revealed key pathogenic pathways, including podocyte injury‐associated protein interaction networks, dysregulated complement activation, and metabolic reprogramming, and have critically assessed their translational potential. Additionally, investigations into posttranslational modifications such as phosphorylation and glycosylation have provided valuable insights for targeted therapies. Collectively, these findings illustrate the contributions of MS‐based proteomics to the characterization of disease molecular heterogeneity, the identification of key pathogenic drivers, and the development of precision medicine approaches. This review further addresses current challenges in clinical applications, including sample heterogeneity, data complexity, and standardization issues. We additionally emphasize the critical need for minimum reporting standards and multicenter harmonization to accelerate the clinical translation of renal proteomics. Future research should focus on integrating multiomics and artificial intelligence‐driven data mining to enhance precise disease subtyping, dynamic monitoring, and personalized treatment strategies.
Subjects
Author keywords
Authors and institutions
- Department of Nephrology, Frontiers Science Center for Disease-related Molecular Network, Institutes for Systems Genetics, West China Hospital, Sichuan University, Chengdu, China.
- Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
- Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology, Chengdu, China.
- Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Pathology, Johns Hopkins University, Maryland, USA.
- Department of Pharmacy, Frontiers Science Center for Disease-related Molecular Network, Institutes for Systems Genetics, West China Hospital, Sichuan University, Chengdu, China.
ORCID profiles: Yingying Ling, Fei Cai, Ling Li, Guisen Li, Rajeev K Singla, Shuyun Liu, Yong Zhang
Funding
- National Natural Science Foundation of China
- National Key R&D Program of China
Cite
APA
Ling, Y., Cai, F., Li, L., Mao, Y., Li, G., Xie, X., Sun, Z., Singla, R. K., Liu, S., Zhao, W., & Zhang, Y. (2026). Advances in Mass Spectrometry‐Based Proteomics for Kidney Disease Biomarker Discovery and Clinical Translation. Mass Spectrometry Reviews. https://doi.org/10.1002/mas.70041
Vancouver
Ling Y, Cai F, Li L, Mao Y, Li G, Xie X, et al. Advances in Mass Spectrometry‐Based Proteomics for Kidney Disease Biomarker Discovery and Clinical Translation. Mass Spectrometry Reviews. 2026. doi:10.1002/mas.70041
BibTeX
@article{Ling2026,
author = {Ling, Yingying and Cai, Fei and Li, Ling and Mao, Yonghong and Li, Guisen and Xie, Xinfang and Sun, Zhenyu and Singla, Rajeev K and Liu, Shuyun and Zhao, Wanjun and Zhang, Yong},
title = {Advances in Mass Spectrometry‐Based Proteomics for Kidney Disease Biomarker Discovery and Clinical Translation},
journal = {Mass Spectrometry Reviews},
year = {2026},
doi = {10.1002/mas.70041}
}
EUVIMED